NGM Bio Announces Initiation of Phase I/Ib Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

NGM Biopharmaceuticals, Inc. announced it has dosed the first patient in a Phase I/Ib clinical trial of NGM831 for the treatment of patients with advanced solid tumors.The trial expects to enroll adult patients with multiple tumor types, including pancreatic cancer, breast cancer and prostate cancer.